Improving radiotherapy quality assurance in clinical trials: Assessment of target volume delineation of the pre-accrual benchmark case

British Journal of Radiology

Volumn 86, Issue 1024, 2013, Pages

  Gwynne, S ^a,b   Spezi, E ^b   Sebag Montefiore, D ^c   Mukherjee, S ^d   Miles, E ^e   Conibear, J ^e   Staffurth, J ^f  

^a SINGLETON HOSPITAL   (United Kingdom)

^b VELINDRE CANCER CENTRE   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MOUNT VERNON CANCER CENTRE   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL ASSESSMENT; ESOPHAGUS CANCER; HUMAN; INTERNAL ILIAC ARTERY; OBSERVER VARIATION; QUALITY CONTROL; REVIEW; SYSTEMATIC ERROR; TREATMENT PLANNING; UNITED KINGDOM; CLINICAL TRIAL (TOPIC); HEALTH CARE QUALITY; IMAGE GUIDED RADIOTHERAPY; PRACTICE GUIDELINE; RADIOTHERAPY; STANDARD; TOTAL QUALITY MANAGEMENT; VALIDATION STUDY;

CLINICAL TRIALS AS TOPIC; GREAT BRITAIN; GUIDELINE ADHERENCE; HUMANS; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT; RADIOTHERAPY; RADIOTHERAPY, IMAGE-GUIDED; VALIDATION STUDIES AS TOPIC;

MLCS; MLOWN;

EID: 84876033212     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.20120398     Document Type: Review

References (44)

1. Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustiq R, et al. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704- a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2012; 82: 809-16. doi:10.1016/j.ijrobp.2010.11.0392011.
2. Peters LJ, O'Sullivan B, Giralt J, Fitzqerald TJ, Trotti A, Bernier J, et al. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2010; 28: 2996-3001.
3. Begnozzi L, Benassi M, Bertanelli M, Bonini A, Cionini L, Cote L, et al. Quality assurances of 3D-CRT: indications and difficulties in their applications. Crit Rev Oncol Haematol 2009; 70: 24-38.
4. Hamilton CS, Ebert MA. Volumetric uncertainty in radiotherapy. Clin Oncol (R Coll Radiol) 2005; 17: 456-64.
5. McLaughlin PW, Evans C, Feng M, Narayana V. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys 2010; 76: 369-78.
6. van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 2004; 14: 52-64.
7. Van de Steene J, Linthout N, de May J, Vinh-Hung V, Claassens C, Noppen M, et al. Definition of gross tumour volume in lung cancer: interobserver variability. Radiother Oncol 2002; 62: 37-49.
8. Weiss E, Hess CF. The impact of gross tumour volume (GTV) and clinical target volume (CTV) definition on the total accuracy in radiotherapy theoretical aspects and practical experiences. Strahlenther Onkol 2002; 179: 21-30.
9. Jansen EP, Nijkamp J, Gubanski M, Lind PA, Verheij M. Interobserver variation of clinical target volume delineation in gastric cancer. Int J Radiat Oncol Biol Phys 2010; 77: 1166-70.
10. Fuller CD, Nijkamp J, Duppen JC, Rasch CR, Thomas CR Jr, Wang SJ, et al. Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. Int J Radiat Oncol Biol Phys 2011; 79: 481-9.
11. Valley JF, Bernier J, Tercier PA, Fogliata-Cozzi A, Rosset A, Garavagila G, et al. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run. Radiother Oncol 1998; 47: 37-44.
12. Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D. Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol 2000; 56: 73-83.
13. Poortmans PM, Veneslaar JL, Struikmans H, Hurkmans CW, Davis JB, Huyskens D, et al. The potential impact of treatment variations on the results of radiotherapy of the internal mammary lymph node chain: a quality-assurance report on the dummy run of EORTC Phase III randomised trial 22922/10925 in Stage I-III breast cancer(1). Int J Radiat Oncol Biol Phys 2001; 49: 1399-408.
14. van Sörnsen de Koste JR, Senan S, Underberg RW, Oei SS, Elshove D, Slotman BJ, et al. Use of CD-rom based tool for analysing contouring variations in involved-field radiotherapy for Stage III NSCLC. Int J Radiat Oncol Biol Phys 2005; 63: 334-9.
15. Coles CE, Hoole AC, Harden SV, Burnet NG, Twyman N, Taylor RE, et al. Qualitative assessment of inter-clinician variability of target volume delineation for medullo-blastoma: a quality assurance for the SIOP PNET 4 trial protocol. Radiother Oncol 2003; 69: 189-94.
16. Mitchell DM, Perry L, Smith S, Elliott T, Wylie JP, Cowan RA, et al. Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphy-sician variation. Int J Radiat Oncol Biol Phys 2009; 75: 990-3.
17. Nijkamp J, de Haas-Kock DFM, Beukema JC, Neelis KJ, Wouternsen D, Ceha H, et al. Target volume delineation in radiotherapy for early stage rectal cancer in the Netherlands. Radio-ther Oncol 2012; 102: 14-21.
18. Khoo EL, Schick K, Plank AW, Poulsen M, Wong WW, Middleton M, et al. Prostate contouring variation: can it be fixed? Int J Radiat Oncol Biol Phys 2012; 82: 1923-9.
19. Dewas S, Bibault JE, Blanchard P, Vautravers-Dewas C, Pointreau Y, Denis F, et al. Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences. Radiat Oncol 2011; 6: 118.
20. Gwynne S, Spezi E, Staffurth J, Palaniappan N, Wills L, Hurt C, et al. Inter-observer variation in outlining of pre-trial test case in the SCOPE1 trial: a United Kingdom definitive chemoradiotherapy trial for esophageal cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1037-42.
21. Glynne-Jones R, Harrison M, Gollins S, Harte R, Maggs R, Ghuman S, et al. The development of a conformal radiotherapy protocol for the Phase III ARISTOTLE rectal cancer trial. Radiother Oncol 2012; 103: S307.
22. Valicenti RK, Sweet JW, Hauck WW, Hudes RS, Lee T, Dicker AP, et al. Variation of clinical target volume definition in three-dimensional con-formal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 931-5.
23. Senan S, van Sörsen de Koste J, Samson M, Tankink H, Jansen P, Nowak PJ, et al. Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. Radiother Oncol 1999; 53: 247-55.
24. Petersen RP, Truong PT, Kader HA, Berthelet E, Lee JC, Hiltz ML, et al. Target volume delineation for partial breast radiotherapy planning: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys 2007; 69: 41-8.
25. Clark CH, Miles EA, Guerrero Urbano MT. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol 2009; 82: 585-94.
26. Szumacher E, Harnett N, Warner S, Kelly V, Danjoux C, Barker R, et al. Effectiveness of educational intervention on the congruence of prostate and rectal contouring as compared with a gold standard in three-dimensional radiotherapy for prostate. Int J Radiat Oncol Biol Phys 2010; 76: 379-85.
27. Lawton CAF, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, et al. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 377-82.
28. Michalski JM, Lawton C, EI Naqa I, Ritter M, O'Meara E, Seider MJ, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010; 76: 361-8.
29. Allozi R, Li XA, White J, Apte A, Tai A, Michalski JM, et al. Tools for consensus analysis of experts' contours for radiotherapy structure definitions. Radiother Oncol 2010; 97: 572-8.
30. Warfield SK, Zou KH, Wells WM. Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation. IEEE Trans Med Imaging 2004; 23: 903-21.
31. Musat E, Roelofs E, Bar-Deroma R, Fenton P, Gulyban A, Collette L, et al. Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: first evaluation of quality of radiotherapy planning. Radiother Oncol 2010; 95: 218-24.
32. Royal College of Radiologist. Imaging for Oncology. Collaboration between Clinical Radiologists and Clinical Oncologists in Diagnosis, Staging and Radiotherapy Planning. Board of the Faculty of Clinical Oncology, The Royal College of Radiologists. London, UK: Royal College of Radiologists; 2004
33. Gwynne S, Spezi E, Hurt C, Falk S, Gollins S, Joseph G, et al. Importance of the reference volume in assessing outlining performance for the purpose of training and revalidation. NCRI Cancer Conference. Liverpool, UK: NCRI, 2012.
34. Pooler AM, Mayles HM, Naismith OF, Sage JP, Dearnaley DP. Evaluation of margining algorithms in commercial treatment planning systems. Radiother Oncol 2008; 86: 43-7.
35. Hanna GG, Hounsell AR, O'Sullivan JM. Geometrical analysis of radiotherapy target volume delineation: a systematic review of reported comparison methods. Clin Oncol 2010; 22: 515-25.
36. Muijs CT, Schreurs LM, Busz DM, Beukema JC, van der Borden AJ, Pruim J, et al. Consequences of additional use of PET information for target volume delineation and radiotherapy dose distribution for eosophageal cancer. Radiother Oncol 2009; 93: 447-53.
37. Jena R, Kirkby NF, Burton KE, Hoole AC, Tan LT, Burnet NG. A novel algorithm for the morpho-metric assessment of radiotherapy treatment planning volumes. Br J Radiol 2010; 83: 44-51.
38. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meat 1960; 20: 37-46.
39. Fotina I, Lütgendorf-Caucig C, Stock M, Pötter R, Gerog D. Critical discussion of evaluation parameters for inter-observer variability in target definition for radiation therapy. Strahlenther Onkol 2012; 188: 160-7.
40. Gwynne S, Hurt C, Spezi E, Crosby T, Staffurth J, Jena R. Mean distance to conformity as a tool for assessing outlining variation in the UK SCOPE 1 oesophageal chemo-radiotherapy trial. Radiother Oncol 2012; 103: S259.
41. Mukherjee S, Halle C, Spezi E, Joseph G, Branagan JMR, Hurt C, et al. Comparison of investigator-delineated GTV in chemoradio-therapy (CRT) for locally advanced non-metastatic pancreatic cancer (LANPC): analysis of the pre-trial test case for the scalop trial. ASCO, GI, San Fransisco; 2013.
42. Cole N, Gwynne S, Spezi E, Maggs R, Sebag-Montefiore D, Adams R. Quality assurance of target volume definition in the ARISTOTLE Phase III rectal cancer trial: initial assessment. Radiother Oncol 2012; 103: S380.
43. Burton K, Jefferies S, Jena R, Estall V, Burnet N. Inter and intra observer variation in the gross tumour volume (GTV) delineation for glioblastoma (GBM). Radiother Oncol 2008; 88: S27.
44. Gwynne S, Spezi E, Joseph G, Hurt C, Staffurth J, Crosby T. Is there a role for more than one test case in pre-trial outlining assessment? NCRI Cancer Conference. Liverpool, UK: NCRI; 2012.